Screener
Allogene Therapeutics ALLO Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 46,092 | 65,191 |
| Loss from operations | (46,092) | (65,191) |
| Other income (expenses), net: | ||
| Interest and other income, net | 3,573 | 5,516 |
| Interest expense | (300) | (150) |
| Other income (expenses), net | 212 | 92 |
| Total other income (expenses), net | 3,485 | 5,458 |
| Net loss | (42,607) | (59,733) |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's interest income?
- Allogene Therapeutics (ALLO) reported interest income of $3.57M in Q1 2026.
- How has Allogene Therapeutics's interest income changed year-over-year?
- Allogene Therapeutics's interest income decreased by 35.2% year-over-year, from $5.52M to $3.57M.
- What is the long-term trend for Allogene Therapeutics's interest income?
- Over 4 years (2021 to 2025), Allogene Therapeutics's interest income has grown at a 83.2% compound annual growth rate (CAGR), from $1.71M to $19.29M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Allogene Therapeutics's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude